• Qiagen posted Q2 net sales flat year on year at USD 535 million.
• GAAP diluted EPS held at USD 0.50; non-GAAP adjusted diluted EPS was USD 0.62.
• Non-GAAP adjusted operating income margin was 29.4% as profitability stayed elevated.
• Growth pillars rose about 5%, while QuantiFERON edged up 1% on lower U.S. immigration testing demand.
• Reaffirmed 2026 outlook for net sales growth of about 1%-2% and non-GAAP adjusted diluted EPS of at least USD 2.43.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 202608051605BIZWIRE_USPR_____20260805_BW194588) on August 05, 2026, and is solely responsible for the information contained therein.